Recent Updates
Recently added Catalysts
NAUT Positive Sentiment

Treasures in the depths of the low abundance proteome

Key Takeaway: The article discusses the significance of low abundance proteins in the human blood proteome and their potential roles in health and disease. It highlights the Nautilus TM Proteome Analysis Platform's capability to identify these proteins, which are often overlooked due to their scarcity. The piece emphasizes the need for comprehensive proteomics studies to unlock the therapeutic potential of these understudied proteins.
Price reaction · baseline $2.7801 (2024-05-02T15:26:00.000Z) · hit during market hours · clean, no other NAUT news in the window
day 0 close · peak
-4%

Market Sentiment Analysis

POSITIVE FACTORS

  • The Nautilus TM Proteome Analysis Platform aims to uncover low abundance proteins.
  • Next-generation proteomics technologies promise to reveal important biological insights.
  • Understanding low abundance proteins can lead to better therapeutic targets.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
MDMA
Phase 2 · Post-Traumatic Stress Disorder

Full Press Release Details

Applications of Proteomics
Tyler Ford
May 2, 2024
Protein levels fall across a wide dynamic range in the proteome . Some high abundance proteins make up a large fraction of the proteome, while low abundance proteins exist only in very small numbers. For example, protein abundances in the human blood proteome span 12 orders of magnitude.
In broadscale proteomics experiments it is critical to quantify proteins at both the high and low abundance ends of this range as both high and low abundance proteins can have impacts on biological function and cellular health.
For our purposes, low abundance proteins are those detected in small amounts compared to other proteins in a sample. There are often orders of magnitude fewer low abundance proteins, and they may be difficult to detect with current proteomics technologies.
In this blog post, we shine a light on some of the fascinating proteins observed at the low abundance end of the blood proteome (all proteins below are in the bottom 10% of the blood proteome as compiled by Deutsch et al 2021 ). While these proteins may not be measured consistently and precisely by current proteomics technologies, learning more about them as part of functional proteomics studies into the human proteome may reveal important biological insights. This post covers only a minuscule fraction of low abundance proteins in the human blood proteome.
The Nautilus TM Proteome Analysis Platform is designed to enable researchers to uncover much more of this “dark proteome” in a consistent, precise, and comprehensive way. We hope proteomics platforms like ours will uncover the treasures hidden in the depths of the proteome and revolutionize the ways we understand health and disease.
Check out this animation to learn how the Nautilus Platform is designed to achieve high dynamic range

Chondromodulin-1 – A critical regulator of cartilage

The chondromodulin-1 protein is thought to play roles in cartilage development and maintenance as well cardiac valve maintenance, among other functions. Dysregulation of this low abundance protein appears to enable some forms of cancer to proliferate while inhibiting others. Researchers are even attempting to direct immunotherapeutic T-cells against c hondromodulin-1 to fight Ewing sarcoma (a type of bone cancer).
It is not clear how chondromodulin-1 achieves its somewhat disparate effects in different cells. Comprehensive functional proteomics could help identify chondromodulin-1 interaction partners and better correlate chondromodulin-1 levels with its effects under different contexts. Such studies would reveal the specific scenarios under which this intriguing protein makes a good therapeutic target.

Bone morphogenetic protein 2 – Roles in bone development, maintenance, and beyond

Bone morphogenetic protein 2 was originally named for its ability to induce bone formation in soft tissues. Since then, researchers have discovered it plays a variety of roles in development (in bones and beyond). This protein continues to have many functions in adults and is particularly well-known for its ability to induce stem cells to differentiate into the osteoblasts and osteoclasts that maintain and repair bones. The FDA has even approved bone morphogenetic protein 2 to aid bone healing.
Despite decades of research into this protein, next-generation proteomics can reveal more about the complex patterns of its activity, including its relationship to other proteins in the human proteome, in a more holistic way. Such work could help refine models of signaling through bone morphogenetic protein 2-induced pathways and enable the development of drugs that precisely modulate these pathways. This may lead to better therapeutics for bone healing and more.

FGF23 – A phosphate regulating hormone with many other roles

Secreted by bone cells, the FGF23 protein plays a strong role in regulating phosphate levels throughout the body. Increased FGF23 in the bloodstream decreases phosphate uptake in numerous tissues including kidney tissues involved in phosphate reabsorption. Beyond its roles in phosphate regulation, FGF23 is believed to be involved in such varied activities as calcium retention, thyroid hormone production, vitamin D synthesis, and more.
Like many proteins in the human proteome, FGF23 comes in various proteoforms , and post-translational modifications modulate its activity. Its phosphorylation leads to degradation and the secretion of FGF23 fragments. FGF23 glycosylation, on the other hand, enables secretion of intact FGF23. Much is known about some aspects of intact FGF23 signaling, but there are still many gaps. It is also unclear what role FGF23 fragments play in signaling. Future targeted proteomics studies of this low abundance protein may help elucidate answers to these questions.
Overall, FGF23 is an incredibly important hormone. Comprehensive functional proteomics can provide more holistic views into the complex associations between FGF23 and the many biological functions it impacts. Such studies should help unravel the tangled web of interactions between FGF23, its fragments, and cellular signaling. This work may highlight important points of therapeutic intervention and help alleviate defects in phosphate metabolism, calcium metabolism, vitamin D metabolism, and more.

A trove of low-abundance proteins in the dark proteome

There are numerous understudied proteins that form the “dark proteome.” Many of these live in the depths of the low-abundance blood proteome and have potential links to disease. A few illustrative examples of these rare blood proteins include:
• TIPRL – A protein implicated as a potential biomarker of aggressive liver cancer.
• VAV2 – A protein involved in a variety of biological processes and recently identified as a mediator of cancer radiotherapy resistance
• Repetin – A calcium binding protein with decreased blood proteome abundance in patients with schizophrenia and bipolar disorder.
There is a great disparity between the number of studies on proteins like these (searching their names in PubMed delivers results numbering in the 10s to 100s) versus highly studied proteins like tumor suppressor p53 (thousands of publications). While one-off papers like those linked above point to the potential importance of the dark proteome, comprehensive proteomics studies will begin to efficiently reveal the many roles these and other understudied proteins play in all manner of healthy functions and disease.

Next-generation proteomics tools for exploring the dark proteome

These proteins may have been difficult to see in the past, but novel proteomics technologies will uncover them, while also enabling functional proteomics studies that show how they interact with the many other proteins across the wide dynamic range of the human proteome.
Only by gaining a comprehensive understanding of these proteins and their many interactions through next-generation proteomics technologies like the Nautilus TM Proteome Analysis Platform can we truly understand the human proteome. Such platforms will enable researchers to develop effective ways to therapeutically target biological processes involving low abundance proteins like these and hopefully improve health outcomes for many people.
Checkout this video to learn how the Nautilus Platform is designed to quantify proteins
Share this Article
Stay up-to-date on all things Nautilus
World-class articles, delivered weekly
MORE ARTICLES
Proteomics applications in medicine, basic biology, and beyond
Proteomics is being applied in many biological fields to unlock new discoveries and drive scientific advances.
Read more
White paper series: The proteomics revolution
This post contains white papers describing how developments in proteomics - led by the Nautilus platform - will improve healthcare.
Read more
Targeting healthcare disparities through the proteomics revolution (Part 1)
Learn how biases have led to inequities in healthcare and how researchers can rectify those inequities with better data.
Read more
Stay up-to-date on all things Nautilus

Subscribe to our Newsletter

Frequently Asked Questions

What are low abundance proteins?

Low abundance proteins are those present in small quantities compared to other proteins in a sample.

How does the Nautilus platform help in proteomics?

The Nautilus TM Proteome Analysis Platform enables consistent and precise detection of low abundance proteins.

What role does chondromodulin-1 play?

Chondromodulin-1 is involved in cartilage development and may influence cancer proliferation.

What is the significance of FGF23?

FGF23 regulates phosphate levels and is involved in various biological functions beyond phosphate metabolism.

Why study the dark proteome?

Studying the dark proteome can reveal important insights into health and disease, highlighting understudied proteins.

Last updated: May 2, 2024